{
    "info": {
        "nct_id": "NCT02949219",
        "official_title": "A Multicenter Phase II Study of Pembrolizumab (MK-3475) in Patients With Advanced Small Bowel Adenocarcinomas",
        "inclusion_criteria": "* Patients must have biopsy-proven adenocarcinoma of the small bowel at any site (duodenum, jejunum, ileum), excluding ampullary and appendiceal tumors\n* Have locally advanced (unresectable) or metastatic small bowel adenocarcinoma\n* Willing and able to provide written informed consent for the trial\n* Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\n* Had at least one prior line of systemic chemotherapy for metastatic disease; adjuvant therapy would not count toward first-line therapy unless patient recurs less than 6 months after completion of that regimen\n* Willing to provide blood and tissue (can be archival) samples for mandatory research purposes\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1\n* Absolute neutrophil count (ANC) >= 1500/mm^3 (1.50 x 10^9 /L) obtained =< 28 days prior to registration\n* Platelet count >= 100,000/mm^3 (100 x 10^9 /L) obtained =< 28 days prior to registration\n* Hemoglobin >= 9.0 g/dL (5.6 mmol/L or 90 g/L) without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) obtained =< 28 days prior to registration\n* Serum total bilirubin =< 1.5 x upper limit of normal (ULN) OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 x ULN obtained =< 28 days prior to registration\n* Aspartate transaminase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases obtained =< 28 days prior to registration\n* Serum creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance must be >= 60 mL/min for subjects with creatinine levels > 1.5 X ULN using the Cockcroft-Gault formula (glomerular filtration rate [GFR] >= 60 mL/min [1.0 mL/s/m^2] can also be used in place of creatinine or creatinine clearance [CrCl]) obtained =< 28 days prior to registration\n* Female subject of childbearing potential have a negative urine or serum pregnancy =< 7 days prior to registration; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n\n  * Note: female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year; male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Non-adenocarcinoma histology\n* Adenocarcinoma originating in the ampulla or appendix; (duodenal tumors that involve the ampulla but originate in the duodenum are eligible)\n* Currently participating and receiving study therapy, or have participated in a study of an investigational agent and received study therapy, or used an investigational device =< 4 weeks of registration\n* Diagnosis of immunodeficiency or be receiving systemic steroid therapy or any other form of immunosuppressive therapy =< 7 days prior to registration\n* History of active TB (bacillus tuberculosis)\n* Hypersensitivity to pembrolizumab or any of its excipients\n* Any of the following:\n\n  * Prior anti-cancer monoclonal antibody (mAb) =< 4 weeks prior to registration\n* Prior chemotherapy, targeted small molecule therapy, or radiation therapy =< 2 weeks prior to registration or who has not recovered to =< grade 1 or baseline from adverse events due to the previously administered agent\n\n  * Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\n* Received major surgery =< 2 weeks prior to registration, subject must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\n* Known additional malignancy that is progressing or requires active treatment or that may interfere with interpretation of response evaluation, in the judgment of the investigator\n* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging =< 4 weeks prior to registration and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids =< 7 days prior to registration; this exception does not include carcinomatous meningitis which is excluded regardless of clinical stability\n* Active autoimmune disease (including but not limited to: patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn?s disease, patients with a history of symptomatic disease [e.g., rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus, autoimmune vasculitis (e.g. Wegener?s granulomatosis)]; CNS or motor neuropathy considered of autoimmune origin [e.g., Guillain-Barre syndrome and myasthenia gravis, multiple sclerosis]) that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment\n* Known history of or any evidence of active, non-infectious pneumonitis\n* Active infection requiring systemic therapy\n* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject?s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator\n* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n* Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment\n* Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or other immune checkpoint inhibitor (e.g. anti-CTLA4)\n* History of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)\n* Known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid RNA [qualitative] is detected)\n* Received a live vaccine within 30 days of planned start of study therapy\n\n  * Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are not allowed",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Hemoglobin >= 9.0 g/dL (5.6 mmol/L or 90 g/L) without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) obtained =< 28 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9.0 g/dL (5.6 mmol/L or 90 g/L)",
                    "criterion": "hemoglobin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5.6,
                                "unit": "mmol/L"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "g/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without transfusion or erythropoietin (EPO) dependency",
                    "criterion": "transfusion or erythropoietin (EPO) dependency",
                    "requirements": [
                        {
                            "requirement_type": "dependency",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "within 7 days of assessment",
                    "criterion": "hemoglobin measurement timing relative to assessment",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 28 days prior to registration",
                    "criterion": "hemoglobin measurement timing relative to registration",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have biopsy-proven adenocarcinoma of the small bowel at any site (duodenum, jejunum, ileum), excluding ampullary and appendiceal tumors",
            "criterions": [
                {
                    "exact_snippets": "biopsy-proven adenocarcinoma of the small bowel at any site (duodenum, jejunum, ileum)",
                    "criterion": "adenocarcinoma of the small bowel",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "adenocarcinoma"
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "biopsy-proven"
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "duodenum",
                                "jejunum",
                                "ileum"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "excluding ampullary and appendiceal tumors",
                    "criterion": "ampullary and appendiceal tumors",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing and able to provide written informed consent for the trial",
            "criterions": [
                {
                    "exact_snippets": "Willing ... to provide written informed consent",
                    "criterion": "willingness to provide written informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "able to provide written informed consent",
                    "criterion": "ability to provide written informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing to provide blood and tissue (can be archival) samples for mandatory research purposes",
            "criterions": [
                {
                    "exact_snippets": "Willing to provide blood ... samples for mandatory research purposes",
                    "criterion": "blood sample",
                    "requirements": [
                        {
                            "requirement_type": "willingness to provide",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "mandatory research"
                        }
                    ]
                },
                {
                    "exact_snippets": "Willing to provide ... tissue (can be archival) samples for mandatory research purposes",
                    "criterion": "tissue sample",
                    "requirements": [
                        {
                            "requirement_type": "willingness to provide",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "sample type",
                            "expected_value": [
                                "fresh",
                                "archival"
                            ]
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "mandatory research"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female subject of childbearing potential have a negative urine or serum pregnancy =< 7 days prior to registration; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required",
            "criterions": [
                {
                    "exact_snippets": "Female subject of childbearing potential",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "negative urine or serum pregnancy =< 7 days prior to registration",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "test type",
                            "expected_value": [
                                "urine pregnancy test",
                                "serum pregnancy test"
                            ]
                        },
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "time before registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count >= 100,000/mm^3 (100 x 10^9 /L) obtained =< 28 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >= 100,000/mm^3 (100 x 10^9 /L)",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm^3"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "10^9 /L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 28 days prior to registration",
                    "criterion": "platelet count measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "time before registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Had at least one prior line of systemic chemotherapy for metastatic disease; adjuvant therapy would not count toward first-line therapy unless patient recurs less than 6 months after completion of that regimen",
            "criterions": [
                {
                    "exact_snippets": "Had at least one prior line of systemic chemotherapy for metastatic disease",
                    "criterion": "prior lines of systemic chemotherapy for metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "adjuvant therapy would not count toward first-line therapy unless patient recurs less than 6 months after completion of that regimen",
                    "criterion": "adjuvant therapy counting toward first-line therapy",
                    "requirements": [
                        {
                            "requirement_type": "recurrence interval after adjuvant therapy",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum total bilirubin =< 1.5 x upper limit of normal (ULN) OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 x ULN obtained =< 28 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Serum total bilirubin =< 1.5 x upper limit of normal (ULN)",
                    "criterion": "serum total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 x ULN",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 28 days prior to registration",
                    "criterion": "timing of laboratory value",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year; male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy",
            "criterions": [
                {
                    "exact_snippets": "female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication",
                    "criterion": "female subjects of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "contraception",
                            "expected_value": "use 2 methods of birth control OR be surgically sterile OR abstain from heterosexual activity"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 120,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "surgical sterilization",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "menses free duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy",
                    "criterion": "male subjects",
                    "requirements": [
                        {
                            "requirement_type": "contraception",
                            "expected_value": "use an adequate method of contraception"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 120,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1500/mm^3 (1.50 x 10^9 /L) obtained =< 28 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1500/mm^3 (1.50 x 10^9 /L)",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "mm^3"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "x 10^9 /L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 28 days prior to registration",
                    "criterion": "date of ANC measurement",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have locally advanced (unresectable) or metastatic small bowel adenocarcinoma",
            "criterions": [
                {
                    "exact_snippets": "locally advanced (unresectable) or metastatic small bowel adenocarcinoma",
                    "criterion": "small bowel adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "disease_status",
                            "expected_value": [
                                "locally advanced (unresectable)",
                                "metastatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance must be >= 60 mL/min for subjects with creatinine levels > 1.5 X ULN using the Cockcroft-Gault formula (glomerular filtration rate [GFR] >= 60 mL/min [1.0 mL/s/m^2] can also be used in place of creatinine or creatinine clearance [CrCl]) obtained =< 28 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine =< 1.5 x upper limit of normal (ULN)",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "measured or calculated creatinine clearance must be >= 60 mL/min for subjects with creatinine levels > 1.5 X ULN using the Cockcroft-Gault formula",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    ]
                },
                {
                    "exact_snippets": "creatinine levels > 1.5 X ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "glomerular filtration rate [GFR] >= 60 mL/min [1.0 mL/s/m^2] can also be used in place of creatinine or creatinine clearance [CrCl]",
                    "criterion": "glomerular filtration rate (GFR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": [
                                "either",
                                "operator: >=, value: 60, unit: mL/min",
                                "operator: >=, value: 1.0, unit: mL/s/m^2"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject?s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator",
            "criterions": [
                {
                    "exact_snippets": "History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial",
                    "criterion": "condition, therapy, or laboratory abnormality",
                    "requirements": [
                        {
                            "requirement_type": "potential to confound trial results",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History or current evidence of any condition, therapy, or laboratory abnormality that might ... interfere with the subject?s participation for the full duration of the trial",
                    "criterion": "condition, therapy, or laboratory abnormality",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with participation for full duration",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History or current evidence of any condition, therapy, or laboratory abnormality that ... is not in the best interest of the subject to participate, in the opinion of the treating investigator",
                    "criterion": "condition, therapy, or laboratory abnormality",
                    "requirements": [
                        {
                            "requirement_type": "not in best interest to participate (investigator opinion)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-adenocarcinoma histology",
            "criterions": [
                {
                    "exact_snippets": "Non-adenocarcinoma histology",
                    "criterion": "histology",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "non-adenocarcinoma"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received a live vaccine within 30 days of planned start of study therapy",
            "criterions": [
                {
                    "exact_snippets": "Received a live vaccine within 30 days of planned start of study therapy",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior anti-cancer monoclonal antibody (mAb) =< 4 weeks prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Prior anti-cancer monoclonal antibody (mAb) =< 4 weeks prior to registration",
                    "criterion": "prior anti-cancer monoclonal antibody (mAb) therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "relative to registration",
                            "expected_value": "prior to registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Currently participating and receiving study therapy, or have participated in a study of an investigational agent and received study therapy, or used an investigational device =< 4 weeks of registration",
            "criterions": [
                {
                    "exact_snippets": "Currently participating and receiving study therapy",
                    "criterion": "participation in a study and receiving study therapy",
                    "requirements": [
                        {
                            "requirement_type": "current participation and therapy receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have participated in a study of an investigational agent and received study therapy",
                    "criterion": "prior participation in a study of an investigational agent and received study therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior participation and therapy receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "used an investigational device =< 4 weeks of registration",
                    "criterion": "use of an investigational device within 4 weeks of registration",
                    "requirements": [
                        {
                            "requirement_type": "time since use",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received major surgery =< 2 weeks prior to registration, subject must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy",
            "criterions": [
                {
                    "exact_snippets": "Received major surgery =< 2 weeks prior to registration",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "timing relative to registration",
                            "expected_value": "prior to registration"
                        }
                    ]
                },
                {
                    "exact_snippets": "subject must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy",
                    "criterion": "recovery from toxicity and/or complications of surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": "adequate"
                        },
                        {
                            "requirement_type": "timing relative to therapy",
                            "expected_value": "prior to starting therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hypersensitivity to pembrolizumab or any of its excipients",
            "criterions": [
                {
                    "exact_snippets": "Hypersensitivity to pembrolizumab",
                    "criterion": "hypersensitivity to pembrolizumab",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Hypersensitivity to ... any of its excipients",
                    "criterion": "hypersensitivity to pembrolizumab excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid RNA [qualitative] is detected)",
            "criterions": [
                {
                    "exact_snippets": "Known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive)",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "HBsAg reactivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid RNA [qualitative] is detected)",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "HCV RNA detection",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known additional malignancy that is progressing or requires active treatment or that may interfere with interpretation of response evaluation, in the judgment of the investigator",
            "criterions": [
                {
                    "exact_snippets": "Known additional malignancy that is progressing",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "progression status",
                            "expected_value": "progressing"
                        }
                    ]
                },
                {
                    "exact_snippets": "Known additional malignancy that ... requires active treatment",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known additional malignancy that ... may interfere with interpretation of response evaluation, in the judgment of the investigator",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with response evaluation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any of the following:",
            "criterions": [
                {
                    "exact_snippets": "Any of the following",
                    "criterion": "unspecified criterion (list to follow)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are not allowed",
            "criterions": [
                {
                    "exact_snippets": "Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed",
                    "criterion": "seasonal influenza vaccine for injection",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "inactivated"
                        },
                        {
                            "requirement_type": "administration route",
                            "expected_value": "injection"
                        },
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are not allowed",
                    "criterion": "intranasal influenza vaccine",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "live attenuated"
                        },
                        {
                            "requirement_type": "administration route",
                            "expected_value": "intranasal"
                        },
                        {
                            "requirement_type": "allowance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adenocarcinoma originating in the ampulla or appendix; (duodenal tumors that involve the ampulla but originate in the duodenum are eligible)",
            "criterions": [
                {
                    "exact_snippets": "Adenocarcinoma originating in the ampulla or appendix",
                    "criterion": "adenocarcinoma primary site",
                    "requirements": [
                        {
                            "requirement_type": "primary site",
                            "expected_value": [
                                "ampulla",
                                "appendix"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging =< 4 weeks prior to registration and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids =< 7 days prior to registration; this exception does not include carcinomatous meningitis which is excluded regardless of clinical stability",
            "criterions": [
                {
                    "exact_snippets": "Known active central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis ... excluded regardless of clinical stability",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging =< 4 weeks prior to registration and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids =< 7 days prior to registration",
                    "criterion": "previously treated brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment_status",
                            "expected_value": "previously treated"
                        },
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "progression by imaging =< 4 weeks prior to registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "neurologic symptoms",
                            "expected_value": "returned to baseline"
                        },
                        {
                            "requirement_type": "new or enlarging brain metastases",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "steroid use =< 7 days prior to registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or other immune checkpoint inhibitor (e.g. anti-CTLA4)",
            "criterions": [
                {
                    "exact_snippets": "Received prior therapy with an anti-PD-1",
                    "criterion": "prior therapy with anti-PD-1 agent",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Received prior therapy with ... anti-PD-L1",
                    "criterion": "prior therapy with anti-PD-L1 agent",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Received prior therapy with ... anti-PD-L2",
                    "criterion": "prior therapy with anti-PD-L2 agent",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Received prior therapy with ... other immune checkpoint inhibitor (e.g. anti-CTLA4)",
                    "criterion": "prior therapy with other immune checkpoint inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to conceive ... within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment",
                    "criterion": "intention or expectation to conceive children",
                    "requirements": [
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "from pre-screening or screening visit through 120 days after the last dose of trial treatment"
                        },
                        {
                            "requirement_type": "expectation",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to ... father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment",
                    "criterion": "intention or expectation to father children",
                    "requirements": [
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "from pre-screening or screening visit through 120 days after the last dose of trial treatment"
                        },
                        {
                            "requirement_type": "expectation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of or any evidence of active, non-infectious pneumonitis",
            "criterions": [
                {
                    "exact_snippets": "Known history of ... active, non-infectious pneumonitis",
                    "criterion": "non-infectious pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial",
            "criterions": [
                {
                    "exact_snippets": "Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial",
                    "criterion": "psychiatric disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "interference with cooperation with the requirements of the trial",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial",
                    "criterion": "substance abuse disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "interference with cooperation with the requirements of the trial",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study",
            "criterions": [
                {
                    "exact_snippets": "subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study",
                    "criterion": "neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "grade"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)",
            "criterions": [
                {
                    "exact_snippets": "History of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of immunodeficiency or be receiving systemic steroid therapy or any other form of immunosuppressive therapy =< 7 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of immunodeficiency",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "receiving systemic steroid therapy ... =< 7 days prior to registration",
                    "criterion": "systemic steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time prior to registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any other form of immunosuppressive therapy ... =< 7 days prior to registration",
                    "criterion": "immunosuppressive therapy (other than systemic steroids)",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time prior to registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of active TB (bacillus tuberculosis)",
            "criterions": [
                {
                    "exact_snippets": "History of active TB (bacillus tuberculosis)",
                    "criterion": "active tuberculosis (TB)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease (including but not limited to: patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn?s disease, patients with a history of symptomatic disease [e.g., rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus, autoimmune vasculitis (e.g. Wegener?s granulomatosis)]; CNS or motor neuropathy considered of autoimmune origin [e.g., Guillain-Barre syndrome and myasthenia gravis, multiple sclerosis]) that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease (including but not limited to: patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn?s disease, patients with a history of symptomatic disease [e.g., rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus, autoimmune vasculitis (e.g. Wegener?s granulomatosis)]; CNS or motor neuropathy considered of autoimmune origin [e.g., Guillain-Barre syndrome and myasthenia gravis, multiple sclerosis])",
                    "criterion": "active autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs)",
                    "criterion": "systemic treatment for autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "treatment_type",
                            "expected_value": [
                                "disease modifying agents",
                                "corticosteroids",
                                "immunosuppressive drugs"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment",
                    "criterion": "replacement therapy for adrenal or pituitary insufficiency",
                    "requirements": [
                        {
                            "requirement_type": "treatment_type",
                            "expected_value": [
                                "thyroxine",
                                "insulin",
                                "physiologic corticosteroid replacement therapy"
                            ]
                        },
                        {
                            "requirement_type": "classification_as_systemic_treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior chemotherapy, targeted small molecule therapy, or radiation therapy =< 2 weeks prior to registration or who has not recovered to =< grade 1 or baseline from adverse events due to the previously administered agent",
            "criterions": [
                {
                    "exact_snippets": "Prior chemotherapy, targeted small molecule therapy, or radiation therapy =< 2 weeks prior to registration",
                    "criterion": "prior chemotherapy, targeted small molecule therapy, or radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "who has not recovered to =< grade 1 or baseline from adverse events due to the previously administered agent",
                    "criterion": "recovery from adverse events due to previously administered agent",
                    "requirements": [
                        {
                            "requirement_type": "severity of adverse events",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "recovery to baseline",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active infection requiring systemic therapy",
            "criterions": [
                {
                    "exact_snippets": "Active infection requiring systemic therapy",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring systemic therapy"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Aspartate transaminase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases obtained =< 28 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Aspartate transaminase (AST) ... =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases ... obtained =< 28 days prior to registration",
                    "criterion": "aspartate transaminase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) ... =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases ... obtained =< 28 days prior to registration",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "=<= 5 x ULN for subjects with liver metastases",
                    "criterion": "aspartate transaminase (AST) level in subjects with liver metastases",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "=<= 5 x ULN for subjects with liver metastases",
                    "criterion": "alanine aminotransferase (ALT) level in subjects with liver metastases",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 28 days prior to registration",
                    "criterion": "timing of laboratory value measurement",
                    "requirements": [
                        {
                            "requirement_type": "time before registration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}